Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the languages menu
  5. Go to the help menu
  6. Go to the modules
  7. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Canadian Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

About us

Content :

Research and Development

The success of a pharmaceutical company hinges on its commitment to developing innovative medicines that bring value to patients trying to manage their health and improve their quality of life.

 

In 2014, the global Sanofi organization dedicated some 4.8 billion euros to research and development. More than 16,000 research staff on three continents are involved in this important work. 

Sanofi possesses one of the richest and most innovative product portfolios in the world, with some 50 therapies under development to treat conditions in seven therapeutic areas: cardiovascular disease, thrombosis, the central nervous system, oncology, diabetes, internal medicine and vaccines.

Canada’s leading role in clinical research

The Clinical Research Unit in Canada represents one of the largest within Sanofi. Our clinical research teams are currently overseeing some 75 clinical trials.

These studies are crucial in determining whether a particular drug is safe and effective, at which dosage, and any potential side effects. Only with all these data can regulatory approval (Health Canada’s “Notice of Compliance”) be obtained and the medicine made available to patients. Once a medicine is on the market, additional studies may be performed to learn more about the effectiveness and safety of the product in various patient groups.

Clinical trials in Canada are most often cooperative projects involving many players, including the pharmaceutical industry, research granting councils and the medical community. They also need the approval of ethics committees and Canadian health authorities. When the studies are completed, the results are analyzed and published, preferably in peer-reviewed journals, to ensure that the data is accepted by the scientific community as valid research.

Canada has an outstanding reputation for clinical research, an international standing built on consistently generating quality data necessary to properly evaluate a drug’s performance. The high level of medical expertise in Canada and the openness of investigative centres to clinical development make Canada attractive for Sanofi's clinical research operations.

In 2014, Sanofi companies in Canada invested $130.5 million in research and development as part of our ongoing commitment as a responsible healthcare partner.

Last update: July 20, 2015

Modules :

Corporate information

Corporate information